136994-78-0

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (3R,4S,5S)-3,4-isopropylidenedioxy-5-hydroxy-cyclohex-1-ene-1-carboxylate is used as an intermediate in the synthesis of Oseltamivir phosphate (O701000), an orally active inhibitor of influenza virus neuraminidase. This antiviral drug is effective in treating and preventing influenza A and B infections, making it a valuable compound in the pharmaceutical industry for addressing public health concerns related to viral outbreaks.
Used in Synthesis of Other Compounds:
Due to its unique structure, ethyl (3R,4S,5S)-3,4-isopropylidenedioxy-5-hydroxy-cyclohex-1-ene-1-carboxylate can also be used as a building block or intermediate in the synthesis of other complex organic compounds with potential applications in various fields, such as agrochemicals, materials science, and specialty chemicals. Its versatility in chemical reactions allows for the development of novel compounds with specific properties and functions.

Upstream product

• 102919-04-0 benzyl 2,3-O-isopropylidene-α-D-lyxo-pentodialdo-1,4-furanoside 
• 77-76-9 2,2-dimethoxy-propane 
• 77-95-2 D-(-)-quinic acid 
• 32384-42-2 (1S,3R,4S,5R)-3,4-O-isopropylidene-1,5-quinic lactone 
• 42411-62-1 (3aR,4R,7S,8aR)-2,2-dimethyl-6-oxotetrahydro-4,7-methano[1,3]dioxolo[4,5-c]oxepin-7(6H)-yl methanesulfonate 
• 141-52-6 sodium ethanolate 
• 136994-75-7 (E)-3-((3aS,4R,6S,6aS)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-2-(diethoxy-phosphoryl)-acrylic acid ethyl ester 
• 136994-76-8 2-(Diethoxy-phosphoryl)-3-((3aS,4R,6aS)-6-hydroxy-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-propionic acid ethyl ester 
• 64-17-5 ethanol 
• 138-59-0 shikimic acid 
• 101769-63-5 (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylic acid ethyl ester 
• 1446467-07-7 C₁₃H₁₇F₃O₇S 
• 108-05-4 vinyl acetate 

Downstream Products

• 158341-64-1 (3R,4S,5S)-3,4,5-trihydroxycyclohex-1-enecarboxylic acid 
• 101769-63-5 (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylic acid ethyl ester 
• 204254-92-2 ethyl (3R,4R,5R)-3-(1-ethyl-propoxy)-4-hydroxy-5-methanesulfonyloxycyclohex-1-ene-1-carboxylate 
• 204254-90-0 ethyl (3aR,7R,7aR)-2,2-dimethyl-7-methanesulfonyloxy-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-carboxylate 
• 204254-84-2 ethyl (3aR,7R,7aR)-2,2-dimethyl-7-methanesulfonyloxy-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-carboxylate 
• 90927-40-5 (3R,4S,5S)-5-hydroxy-3,4-(isopropylidenedioxy)cyclohex-1-enecarboxylic acid 

Relevant academic research and scientific papers

Stereodivergent Syntheses of All Stereoisomers of (?)-Shikimic Acid: Development of a Chiral Pool for the Diverse Polyhydroxy-cyclohexenoid (or -cyclohexanoid) Bioactive Molecules

Novel stereodivergent total syntheses of all the seven stereoisomers of (?)-shikimic acid [(?)-SA 1] have been systematically performed. (+)-ent-SA ent-1 was synthesized from (?)-SA 1 via 9 steps in 31 % overall yield; (?)-3-epi-SA 2 was synthesized from (?)-SA 1 via 5 steps in 66 % overall yield; (+)-3-epi-ent-SA ent-2 was synthesized from (?)-SA 1 via 7 steps in 43 % overall yield; (?)-4-epi-SA 3 was synthesized from (?)-SA 1 via 11 steps in 32 % overall yield; (+)-4-epi-ent-SA ent-3 was synthesized from (?)-SA 1 via 7 steps in 42 % overall yield; (?)-5-epi-SA 4 was synthesized from (?)-SA 1 via 6 steps in 56 % overall yield; and (+)-5-epi-ent-SA ent-4 was synthesized from (?)-SA 1 via 12 steps in 29 % overall yield. The stereochemistry of all the above seven stereoisomers of (?)-SA 1 were further studied by two dimensional (2D) 1H NMR technique.

Process for synthesizing oseltamivir sulfonate from quinic acid

The invention discloses a process for synthesizing oseltamivir sulfonate from quinic acid. The process specifically comprises the following steps of: S1, adding quinic acid and ethyl acetate into a round-bottom flask, and adding p-toluenesulfonic acid and 2, 2-dimethoxypropane, carrying out reaction to obtain a brown solid 2; S2, adding the brown solid 2 and dichloromethane into the round-bottom flask, dropwise adding methanesulfonyl chloride and triethylamine into the round-bottom flask while performing stirring, and carrying out reaction to obtain an intermediate 3; S3, adding the obtained intermediate 3 into a three-neck flask, adding ethanol and sodium ethoxide for reaction, and removing the dichloromethane after finishing the reaction to obtain an intermediate 4; and S4, adding the intermediate 4 and dichloromethane into the round-bottom flask, dropwise adding the methanesulfonyl chloride and triethylamine into the round-bottom flask while performing stirring, extracting a reaction solution with dichloromethane and water after finishing the reaction, concentrating an obtained organic phase under reduced pressure, adding methanol for crystallization, and performing filtering toobtain a white crystal 5, namely oseltamivir sulfonate.

Synthesis method of daphenanthrene key intermediate

The invention relates to a synthetic method of a Duffy key intermediate. The synthetic method comprises the following steps of by taking shikimic acid as a starting material and performing reactions including esterification reaction, selective oxidation a

Cyclohexenes derivative or its pharmaceutically acceptable salts and its use

Belonging to the field of pharmaceutical chemistry, the invention discloses a cyclohexene derivative shown as formula I or its pharmaceutically acceptable salt. The cyclohexene derivative or its pharmaceutically acceptable salt has good inhibitory activit

Chemo-enzymatic enantioconvergent approach toward ethyl shikimate from ethyl 5-hydroxy-3,4-isopropylidenedioxycyclohex-1-enecarboxylate

An enantioconvergent route for natural form of ethyl shikimate was achieved from Diels-Alder adduct of furan and acryloyl chloride. The key step was a highly enantioselective (E >500) and efficient acetylation of ethyl (3R*,4S*,5S*)-5-hydroxy-3,4-isopropylidenedioxycyclohex-1- enecarboxylate, which had a diastereomeric relationship with ethyl shikimate, mediated by Burkholderia cepacia lipase (Amano PS-IM). Both of the resolved enantiomers were converted to natural form of ethyl shikimate by inversion at C-5 for the former and at C-3 and C-4 for the latter, respectively.

Industrial synthesis of the key precursor in the synthesis of the anti-influenza drug oseltamivir phosphate (Ro 64-0796/002, GS-4104-02): Ethyl (3R,4S,5S)-4,5-epoxy-3-(1-ethyl-propoxy)-cyclohex-1 -ene-1 -carboxylate

Starting from (-)-quinic acid, the title compound was synthesized in seven chemical steps and an overall yield of 35-38%. The route of the improved Gilead synthesis was not changed. However, significant improvements in each step led to a doubled overall yield, a 30% reduction in the number of unit operations, and an excellent quality (≥99%) of the resulting epoxide. A highly regioselective method for the dehydration of a quinic acid to a shikimic acid derivative and for the reduction of a cyclic ketal was found. Alternatively, the title compound was synthesized in six chemical steps and 63-65% yield from commercially available (-)-shikimic acid. Compared to the optimized quinic acid route, the production time was reduced by about 50%. The quality of epoxide produced from either natural product was equivalent. Therefore (-)-shikimic acid is the preferred raw material. The absolute configuration of the epoxide was determined by X-ray single crystal structure analysis and it was demonstrated that the epoxide was stereo-isomerically pure.

Synthesis of shikimic acid and its phosphonate analogue via knoevenagel condensation

The Knoevenagel condensation and intramolecular olefination have been successfully exploited in a novel synthesis of shikimic acid 1 and its phosphonate analogue 2 from D-lyxose 5-aldehyde 7.